BAYER CONSUMER CARE AG;BAYER PHARMA AKTIENGESELLSCHAFT
发明人:
Bernard HAENDLER
申请号：
US16624156
公开号：
US20200222414A1
申请日:
2018.06.21
申请国别(地区):
US
年份:
2020
代理人:
摘要：
The present invention relates to: * combinations of: * a component A: which is a PI3K kinase inhibitor, such as co-panlisib, or a stereoisomer, a tautomer, an N-oxide, a hydrate, a solvate, or a salt thereof, in particular a physiologically acceptable salt, or a mixture of same, for example； * a component B: which is an androgen receptor antagonist, such as darolutamide or enzalutamide for example； and, optionally, * one or more pharmaceutical agents C； in which optionally either or both of said components A and B are in the form of a pharmaceutical formulation which is ready for use to be administered simultaneously, concurrently, separately or sequentially； * use of such combinations: * in the treatment or prophylaxis of a cancer, particularly prostate cancer, or * for the preparation of a medicament for the treatment or prophylaxis of a cancer, particularly prostate cancer； * methods of treatment or prophylaxis of a cancer, particularly prostate cancer, in a subject, comprising administering to said subject a therapeutically effective amount of such a combination； * compositions containing such a combination, together with pharmaceutically acceptable ingredients； and * kits comprising such a combination.
